Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)
Tonix Pharmaceuticals enrolled the first patient in the HORIZON Phase 2 study, evaluating TNX-102 SL as a first-line monotherapy for Major Depressive Disorder (MDD). The potentially pivotal study aims to enroll approximately 360 patients across 30 U.S. sites over 6 weeks, with the primary endpoint measuring change in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score.
Key figures
- Drug Name
- TNX-102 SL
- Phase Of Trial
- Phase 2
- Sites
- 30
- Dosage mg
- 5.6
- Patients expected
- 360
- Treatment duration weeks
- 6
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.